No Data
No Data
JMP Securities Reiterates Market Outperform on CureVac, Maintains $16 Price Target
JMP Securities Maintains CureVac(CVAC.US) With Buy Rating, Maintains Target Price $16
JMP Securities analyst Roy Buchanan maintains $CureVac(CVAC.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 25.8% and a
CureVac's Promising Cancer Vaccine Candidate CVGBM Elicits Buy Rating
CureVac Shares Are Trading Higher After the Company Presented Its CVGBM Cancer Vaccine Results From Its Phase 1 Study of Glioblastoma at the ESMO 2024 Congress.
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza MRNA Vaccine
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal